Various Vertigo Syndromes

  • Thomas Brandt
  • Marianne Dieterich
  • Michael Strupp


Here vertigo and dizziness in childhood are described first. The most frequent syndrome is benign paroxysmal vertigo of childhood, a form of vestibular migraine. Benign paroxysmal positional vertigo, Menière’s disease, vestibular neuritis, perilymph fistula, bilateral vestibulopathy, and central vestibular syndromes also occur in childhood.

This part also includes
  • Drug-induced vertigo

  • Cervicogenic vertigo

  • Episodic ataxias

  • Motion sickness (clinical aspects and pathogenesis, course, prophylaxis, and therapy)

  • Visual height intolerance and fear of heights (acrophobia)


Motion Sickness Benign Paroxysmal Positional Vertigo Vestibular Neuritis Vestibular Migraine Episodic Ataxia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abu-Arafeh I, Russel G. Paroxysmal vertigo as a migraine equivalent in children: a population-based study. Cephalalgia. 1995;15:22–5.PubMedCrossRefGoogle Scholar
  2. Agras WS, Chapin HN, Oliveau DC. The natural history of phobia. Arch Gen Psychiatry. 1972;26:315–7.PubMedCrossRefGoogle Scholar
  3. Alvina K, Khodakhah K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci. 2010;30:7258–68.PubMedCrossRefGoogle Scholar
  4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM IV). 4th ed. Washington: American Psychiatric Association; 1994.Google Scholar
  5. Baier B, Winkenwerder E, Dieterich M. Vestibular migraine: effects of prophylactic therapy with various drugs. A retrospective study. J Neurol. 2009;256:426–42.Google Scholar
  6. Balatsouras DG, Kaberos A, Assimakopoulos D, Katotomichelakis M, Economou NC, Korres SG. Etiology of vertigo in children. Int J Pediatr Otorhinolaryngol. 2007;71:487–94.PubMedCrossRefGoogle Scholar
  7. Basser LS. Benign paroxysmal vertigo of childhood. A variety of vestibular neuronitis. Brain. 1964;87:141–52.PubMedCrossRefGoogle Scholar
  8. Bauer M, Huppert D, Brandt T. Fear of heights in ancient China. J Neurol. 2012;259:2223–5.PubMedCrossRefGoogle Scholar
  9. Bertholon P, Chabrier S, Riant F, Tournier-Lasserve E, Peyron R. Episodic ataxia type 2: unusual aspects in clinical and genetic presentation. Special emphasis in childhood. J Neurol Neurosurg Psychiatry. 2010;80:1289–92.CrossRefGoogle Scholar
  10. Bickerstaff ER. Basilar artery migraine. Lancet. 1961;1:15–8.CrossRefGoogle Scholar
  11. Blakley BW, Gulati H. Identifying drugs that cause dizziness. Otolaryngology. 2008;37:11–5.Google Scholar
  12. Bles W, Kapteyn TS, Brandt T, Arnold F. The mechanism of physiological height vertigo: II. Posturography. Acta Otolaryngol (Stockh). 1980;89:534–40.CrossRefGoogle Scholar
  13. Bles W, Bos JE, Kruit H. Motion sickness. Curr Opin Neurol. 2000;13:19–25.PubMedCrossRefGoogle Scholar
  14. Boldingh MI, Ljostad U, Mygland A, Monstad P. Vestibular sensitivity in vestibular migraine: VEMP’s and motion sickness susceptibility. Cephalalgia. 2011;31:1211–9.PubMedCrossRefGoogle Scholar
  15. Brandt T. Optisch-vestibuläre Bewegungskrankheit, Höhenschwindel und klinische Schwindelformen. Fortschr Med. 1976;94:177–1188.Google Scholar
  16. Brandt T. Cervical vertigo – reality or fiction? Audiol Neurotol. 1996;1:187–96.CrossRefGoogle Scholar
  17. Brandt T, Bronstein AM. Cervical vertigo. J Neurol Neurosurg Psychiatry. 2001;71:8–12.PubMedCrossRefGoogle Scholar
  18. Brandt T, Strupp M. Episodic ataxia type 1 and 2 (familial periodic ataxia/vertigo). Audiol Neurotol. 1997;2:373–83.CrossRefGoogle Scholar
  19. Brandt T, Wenzel D, Dichgans J. Die Entwicklung der visuellen Stabilisation des aufrechten Standes beim Kind: Ein Reifezeichen in der Kinderneurologie. Arch Psychiat Nervenkr. 1976;223:1–13.PubMedCrossRefGoogle Scholar
  20. Brandt T, Arnold F, Bles W, Kapteyn TS. The mechanism of physiological height vertigo: I.Theoretical approach and psychophysics. Acta Otolaryngol (Stockh). 1980;89:513–23.CrossRefGoogle Scholar
  21. Brandt T, Benson J, Huppert D. What to call “non-phobic” fear of heights? Br J Psychiatry. 2012a;190:81. doi: 10.1192/bjp190.1.81a.Google Scholar
  22. Brandt T, Strupp M, Huppert D. Height intolerance – an underrated threat. J Neurol. 2012b;259:759–60.PubMedCrossRefGoogle Scholar
  23. Brown JJ, Baloh RW. Persistent mal de debarquement-syndrome: a motion-induced subjective disorder of balance. Am J Otolaryngol. 1987;8:219–22.PubMedCrossRefGoogle Scholar
  24. Brunt ER, van Weerden TW. Familial paroxysmal kinesiogenic ataxia and continuous myokymia. Brain. 1990;113:1361–82.PubMedCrossRefGoogle Scholar
  25. Cha YH. Mal de debarquement. Semin Neurol. 2009;29:520–7.PubMedCrossRefGoogle Scholar
  26. Cha YH, Chakrapani S, Craig A, Baloh RW. Metabolic and functional connectivity changes in mal de debarquement syndrome. PLoS One. 2012;7:e49560.PubMedCrossRefGoogle Scholar
  27. Cha YH, Cui Y, Baloh RW. Repetitive transcranial magnetic stimulation for mal de debarquement syndrome. Otol Neurotol. 2013;34:175–9.PubMedCrossRefGoogle Scholar
  28. Cianfrone G, Pentangelo D, Cianfrone E, Mazzei F, Turchetta R, Orlando MP, et al. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and update guide. Eur Rev Med Pharmacol Sci. 2011;15:601–36.PubMedGoogle Scholar
  29. Clark BC, Leporte A, Clark S, Hoffman RL, Quick A, Wilson TE, et al. Effects of persistent mal de debarquement syndrome on balance, psychological traits, and motor cortex excitability. J Clin Neurosci. 2013;20:446–50.PubMedCrossRefGoogle Scholar
  30. Coelho CM, Wallis G. Deconstructing acrophobia: physiological and psychological precursors to developing a fear of heights. Depress Anxiety. 2010;27:864–70.PubMedCrossRefGoogle Scholar
  31. Cuomo-Granston A, Drummond PD. Migraine and motion sickness: what is the link? Prog Neurobiol. 2010;91:300–12.PubMedCrossRefGoogle Scholar
  32. Curtis GC, Magee WJ, Eaton WW, Wittchen HU. Specific fears and phobias. Epidemiology and classification. Br J Psychiatry. 1998;173:212–7.PubMedCrossRefGoogle Scholar
  33. Dai M, Raphan T, Cohen B. Labyrinthine lesions and motion sickness susceptibility. Exp Brain Res. 2007;178:477–87.CrossRefGoogle Scholar
  34. De Jong IMBV, Bles W. Cervical dizziness and ataxia. In: Bles W, Brandt T, editors. Disorders of posture and gait. Amsterdam/New York/Oxford: Elsevier; 1986. p. 185–206.Google Scholar
  35. De Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, et al. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci. 2011;108:6621–5.PubMedCrossRefGoogle Scholar
  36. Depla MFIA, ten Have ML, van Balkom AJLM, de Graf R. Specific fears and phobias in the ­general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 2008;43:200–8.PubMedCrossRefGoogle Scholar
  37. Dichgans J, Brandt T. Optokinetic motion-sickness and pseudo-coriolis effects induced by moving visual stimuli. Acta Otolaryngol. 1973;76:339–48.PubMedCrossRefGoogle Scholar
  38. Dichgans J, Brandt T. Visual-vestibular interaction: effects of self-motion perception and postural control. In: Held R, Leibowitz HW, Teuber HL, editors. Handbook of Sensory Physiology, Perception, vol. III. Berlin/Heidelberg/New York: Springer; 1978. p. 755–804.Google Scholar
  39. Dieterich M, Pöllmann W, Pfaffenrath V. Cervicogenic headache: electronystagmography, ­perception of verticality and posturography in patients before and after C2-blockade. Cephalalgia. 1993;13:285–8.PubMedCrossRefGoogle Scholar
  40. Erbek SH, Erbek SS, Yilmaz I, Topal O, Ozgirgin N, Ozluoglu LN, et al. Vertigo in childhood: a clinical experience. Int J Pediatr Otorhinolaryngol. 2006;70:1547–54.PubMedCrossRefGoogle Scholar
  41. Evans RW, Marcus D, Furman JM. Motion sickness and migraine. Headache. 2007;47:607–10.PubMedCrossRefGoogle Scholar
  42. Gil A, Nachum Z, Tal D, Shupak A. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in a naval crew: a double-blind, randomized, crossover study. Clin Neuropharmacol. 2012;35:37–9.PubMedCrossRefGoogle Scholar
  43. Golding IF, Markey HM, Stott IR. The effects of motion direction, body axis, and posture on motion sickness induced by low frequency linear oscillation. Aviat Space Environ Med. 1995;66:1046–51.PubMedGoogle Scholar
  44. Griggs RC, Nutt JG. Episodic ataxias as channelopathies. Ann Neurol. 1995;37:285–7.PubMedCrossRefGoogle Scholar
  45. Griggs RC, Moxley RT, Lafrance RA, McQuillen J. Hereditary paroxysmal ataxia: response to acetazolamide. Neurology. 1978;28:1259–64.PubMedCrossRefGoogle Scholar
  46. Holtmann S, Reiman V, Schöps P. Clinical significance of cervico-ocular reactions. Laryngorhinootologie. 1993;72:306–10.PubMedCrossRefGoogle Scholar
  47. Huppert D, Strupp M, Mückter H, Brandt T. Which medication do I need to manage dizzy patients? Acta Otolaryngol. 2011;131:228–41.PubMedCrossRefGoogle Scholar
  48. Huppert D, Grill E, Brandt T. Down on heights? One in three has visual height intolerance. J Neurol. 2013;260:597–604.PubMedCrossRefGoogle Scholar
  49. Jahn K, Zwergal A, Strupp M, Brandt T. Schwindel im Kindesalter. Nervenheilkunde. 2009;28:47–52.Google Scholar
  50. Jahn K, Langhagen T, Schroeder AS, Heinen F. Vertigo and dizziness in childhood – update on diagnosis and treatment. Neuropediatrics. 2011;42:129–34.PubMedCrossRefGoogle Scholar
  51. Jen JC. Hereditary episodic ataxias. Ann N Y Acad Sci. 2008;1142:250–3.PubMedCrossRefGoogle Scholar
  52. Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology. 2004;62:17–22.PubMedCrossRefGoogle Scholar
  53. Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain. 2007;130:2484–93.PubMedCrossRefGoogle Scholar
  54. Kanaan AA, Raad RA, Hourani RG, Zaytoun GM. Bilateral superior semicircular canal dehiscence in a child with sensorineural hearing loss and without vestibular symptoms. Int J Pediatr Otorhinolaryngol. 2011;75:877–9.PubMedCrossRefGoogle Scholar
  55. Knox GW, Woodard D, Chelen W, Ferguson R, Johnson L. Phenytoin for motion sickness: clinical evaluation. Laryngoscope. 1994;1994:935–9.Google Scholar
  56. Krams B, Echenne B, Leydet J, Rivier F, Roubertie A. Benign paroxysmal vertigo of childhood: long-term outcome. Cephalalgia. 2011;31:439–43.PubMedCrossRefGoogle Scholar
  57. Lanzi G, Balottin U, Fazzi E, Tagliasacchi M, Manfrin M, Mira E. Benign paroxysmal vertigo of childhood: a long-term follow-up. Cephalalgia. 1994;14:458–60.PubMedCrossRefGoogle Scholar
  58. Lee GS, Zhou G, Poe D, Kenna M, Amin M, Ohlms L, et al. Clinical experience in diagnosis and management of superior semicircular canal dehiscence in children. Laryngoscope. 2011;121:2256–61.PubMedCrossRefGoogle Scholar
  59. Macke A, LePorte A, Clark BC. Social, societal, and economic burden of mal de debarquement syndrome. J Neurol. 2012;259:1326–30.PubMedCrossRefGoogle Scholar
  60. Moeller L, Lempert T. Mal de debarquement: pseudo-hallucinations from vestibular memory? J Neurol. 2007;254:813–5.PubMedCrossRefGoogle Scholar
  61. Money KE. Motion sickness. Physiol Rev. 1970;50:1–39.PubMedGoogle Scholar
  62. Murdin L, Golding J, Bronstein A. Managing motion sickness. BMJ. 2011;343:d7430.PubMedCrossRefGoogle Scholar
  63. Murphy TP. Mal de debarquement syndrome: a forgotten entity? Otolaryngol Head Neck Surg. 1993;109:10–3.PubMedGoogle Scholar
  64. Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: a diagnostic challenge. Cephalalgia. 2004;24:83–91.PubMedCrossRefGoogle Scholar
  65. Niemensivu R, Kentala E, Wiener-Vacher S, Pyykko I. Evaluation of vertiginous children. Eur Arch Otorhinolaryngol. 2007;264:1129–35.PubMedCrossRefGoogle Scholar
  66. Noyes R, Clancy J, Hoenk PR, Slymen DJ. The prognosis of anxiety neurosis. Arch Gen Psychiatry. 1980;37:173–8.PubMedCrossRefGoogle Scholar
  67. Probst T, Krafczyk S, Büchele W, Brandt T. Visuelle Prävention der Bewegungskrankheit im Auto. Arch Psychiat Nervenkr. 1982;231:409–21.PubMedCrossRefGoogle Scholar
  68. Pull CB. Current status of virtual reality exposure therapy in anxiety disorders: editorial review. Curr Opin Psychiatry. 2005;18:7–14.PubMedGoogle Scholar
  69. Rascol O, Hain TC, Brefel C, Benazet M, Clanet M, Montastruc JL. Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs. 1995;50:777–91.PubMedCrossRefGoogle Scholar
  70. Reason JT. Motion sickness adaptation: a neural mismatch model. J R Soc Med. 1978;71:819–29.PubMedGoogle Scholar
  71. Riina N, Ilmari P, Kentala E. Vertigo and imbalance in children: a retrospective study in a Helsinki University otorhinolaryngology clinic. Arch Otolaryngol Head Neck Surg. 2005;131:996–1000.PubMedCrossRefGoogle Scholar
  72. Ritter B. Treatment of acrophobia with contact desensibilisation. Behav Res Ther. 1969;7:41–5.PubMedCrossRefGoogle Scholar
  73. Russel G, Abu-Arafeh I. Paroxysmal vertigo in children- an epidemiological study. Int J Pediatr Otorhinolaryngol. 1999;49(1):105–7.CrossRefGoogle Scholar
  74. Salassa JR, Zapala DA. Love and fear of heights: the pathophysiology and psychology of height imbalance. Wilderness Environ Med. 2009;20:378–82.PubMedCrossRefGoogle Scholar
  75. Shoair OA, Nyandege AN, Slattum PW. Medication-related dizziness in the oder adult. Otolaryngol Clin North Am. 2011;44:455–71.PubMedCrossRefGoogle Scholar
  76. Shupak A, Gordon CR. Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med. 2006;77:1213–23.PubMedGoogle Scholar
  77. Spinks AB, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev. 2011;6:CD002851.Google Scholar
  78. Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology. 2004;62:1623–5.PubMedCrossRefGoogle Scholar
  79. Strupp M, Zwergal A, Brandt T. Episodic ataxia type 2. Neurotherapeutics. 2007;4:267–73.PubMedCrossRefGoogle Scholar
  80. Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T, et al. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology. 2011;77:269–75.PubMedCrossRefGoogle Scholar
  81. Tinetti ME. Preventing falls in elderly persons. N Engl J Med. 2002;348:42–9.CrossRefGoogle Scholar
  82. Walk RD, Gibson EJ, Tighe TJ. Behaviour of light- and dark-raised rats on a visual cliff. Science. 1957;126:80–1.PubMedCrossRefGoogle Scholar
  83. Wolpe J. Psychotherapy by reciprocal inhibition. Stanford: Stanford University Press; 1958.Google Scholar
  84. Wood CD, Graybiel A. Evaluation of antimotion sickness drugs: a new effective remedy revealed. Aerosp Med. 1970;41:932–3.PubMedGoogle Scholar
  85. Wood CD, Graybiel A, Kennedy RS. Comparison of effectiveness of some antimotion sickness drugs using recommended and larger than recommended doses as tested in the slow rotation room. Aerospace Med. 1966;37:259–62.PubMedGoogle Scholar
  86. Zhang D, Fan Z, Han Y, Wang M, Xu L, Luo J, et al. Benign paroxysmal vertigo of childhood: diagnostic value of vestibular test and high stimulus rate auditory brainstem response test. Int J Pediatr Otorhinolaryngol. 2012;76:107–10.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Thomas Brandt
    • 1
  • Marianne Dieterich
    • 2
  • Michael Strupp
    • 2
  1. 1.Clinical Neurosciences and Center for Vertigo & Balance DisordersUniversity of MunichMunichGermany
  2. 2.Department of Neurology and Center for Vertigo & Balance DisordersUniversity of MunichMunichGermany

Personalised recommendations